SUCCESFUL RITUXIMAB THERAPY OF MEMBRANOUS NEPHROPATHY, RESISTANT TO STANDARD IMMUNOSUPRESSIVE TREATMENT


Cite item

Full Text

Abstract

Rituximab therapy of patient with idiopathic membranous nephropathy resistant to previous immunosuppressive treatment is described.

References

  1. Donadio J.V. Jr., Torres V.E., Velosa J.A. et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988; 33: 708-715.
  2. Noel L.H., Zanetti M., Droz D., Barbanel C. Long-term prognosis of idiopathic membranous glomerulonephritis: study of 116 untreated patients. Am J Med. 1978; 66: 82-90.
  3. Hogan S.L., Muller K.E., Jennette J.C., Falk R.J. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995; 25(6): 862-875.
  4. Deegens J.K., Wetzels J.F. Diagnosis and treatment of primary glomerular diseases. Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy. Minerva Urol Nefrol. 2005; 57(3): 211-236.
  5. Schena P. Survey of the Italian Registry of Renal Biopsies: frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant. 1997; 12: 418-426.
  6. Haas M., Meehan S.M., Karrison T.G., Spargo B.H. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997; 30: 621-631.
  7. Filler G., Young E., Geier P. et al. Is there really an increase in non-minimal change nephritic syndrome in children? Am J Kidney Dis. 2003; 42: 1107-1113.
  8. Ruggenenti P., Cravedi P., Remuzzi G. Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother. 2007; 8(18): 3159-3171.
  9. Quaglia M., Stratta P. Idiopathic membranous nephropathy: management strategies. Drugs. 2009; 69(10): 1303-1317.
  10. Мухин Н.А., Козловская Л.В., Шилов Е.М., Мирошниченко Н.Г. Мембранозная нефропатия: как дифференцировать первичный и паранеопластический варианты? Клиническая нефрология. 2009; 2: 75-78.
  11. Reichert L.J., Koene R.A., Wetzels J.F. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis. 1998; 31: 1-11.
  12. Glassock R.J. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003; 23: 324-332.
  13. Schieppati A., Mosconi L., Perna A. et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993; 329: 85-89.
  14. Jha V., Ganguli A., Saha T.K. et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007; 18: 1899-1904.
  15. Li X., Li H., Ye H. et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis. 2009; 54(1): 51-58.
  16. Aaltonen S., Honkanen E. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy. Nephrol Dial Transplant. 2011; Epub ahead of print. doi: 10.1093/ndt/gfq841.
  17. Cattran D.C., Appel G.B., Hebert L.A. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int. 2001; 59: 1484-1490.
  18. Praga M., Barrio V., Fernandez Juarez G. et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007; 71: 924-930.
  19. Ballarin J., Proveda R., Ara J. et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant. 2007; 22: 3196-3201.
  20. Kalliakmani P., Koutroulia E., Sotsiou F. et al. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy. Nephrology (Carlton). 2010; 15: 762-767.
  21. Мухин Н.А., Тареева И.Е., Краснова Т.Н., Шилов Е.М., Мирошниченко Н.Г. Лечение нефротической формы гломерулонефрита сандиммуном (циклоспорином А). Тер арх. 1995; 67(8): 13-15.
  22. Краснова Т.Н., Тареева И.Е., Шилов Е.М., Мухин Н.А., Мирошниченко Н.Г. Сандиммун в лечении хронического гломерулонефрита с нефротическим синдромом. Тер арх. 1995; 69(6): 21-23.
  23. Игнатова М.С., Турпитко О.Ю., Харина Е.А. и др. Результаты многоцентрового изучения эффективности циклоспорина А при нефротическом синдроме у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2008; 87(5): 87-91.
  24. Козловская Л.В. Хронический гломерулонефрит: аргументы в пользу применения циклоспорина. Клиническая нефрология. 2010; 3: 56-61.
  25. Dussol B., Morange S., Burtey S. et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008; 52: 699-705.
  26. Branten A.J.W., du Buf-Vereijken P.W.G., Vervloet M. et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007; 50: 248-256.
  27. Hofstra J.M., Wetzels J.F.M. Management of patients with membranous nephropathy Nephrol Dial Transplant. 2011; 0: 1-4.
  28. Приходина Л.С., Турпитко О.Ю., Длин В.В., Игнатова М.С. Микофенолата мофетил в лечении стероид-резистентного нефротического синдрома у детей. Клиническая нефрология. 2011; 2: 56-60.
  29. Столяревич Е.С., Ведерникова Р.Н, Томилина Н.А. Переносимость препаратов микофеноловой кислоты у пациентов с гастроинтестинальными побочными эффектами на поздних сроках после аллотрансплантации почки. Нефрология и диализ. 2007; 9(2): 180-186.
  30. Kerjaschki D., Neale T.J. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol. 1996; 7: 2518-2526.
  31. Cohen C.D., Calvaresi N., Armelloni S. et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol. 2005; 18: 328-333.
  32. Ponticelli C., Zucchelli P., Passerini P. et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989; 320: 8-13.
  33. Bomback A.S., Derebail V.K., McGregor J.G. et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol. 2009; 4: 734-744.
  34. Ponticelli C., Zucchelli P., Passerini P., Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 1992; 327: 599-603.
  35. Cravedi P., Ruggenenti P., Sghirlanzoni M.C., Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007; 2: 932-937.
  36. Ruggenenti P., Chiurchiu C., Abbate M. et al. Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol. 2006; 1: 738-748.
  37. Anolik J.H., Campbell D., Felgar R.E. et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48(2): 455- 459.
  38. Fervenza F.C., Cosio F.G., Erickson S.B. et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73: 117- 125.
  39. Мухин Н.А., Семенкова Е.Н., Кривошеев О.Г., Новиков П.И. Применение ритуксимаба при тяжелых АНЦА- ассоциированных системных васкулитах. Клиническая нефрология. 2010; 2: 40-45.
  40. Ruggenenti P., Cravedi P., Sghirlanzoni M.C. et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol. 2008; 3: 1652-1659.
  41. Fervenza F.C., Abraham R.S., Erickson S.B. et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010; 5: 2188-2198.
  42. Segarra A., Praga M., Ramos N. et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor dependent patients. Clin J Am Soc Nephrol. 2009; 4: 1083-1088.
  43. Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxf). 2001; 40: 205-211.
  44. Keogh K.A., Wylam M.E., Stone J.H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52: 262-268.
  45. Насонов Е.Л. Перспективы применения ритуксимаба при аутоиммунных заболеваниях человека. Русский медицинский журнал. 2007; 15(26): 1-6.
  46. Roll P., Dorner T., Tony H.P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008; 58: 1566-1575.
  47. Martin F., Chan A.C. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity. 2004; 20: 517- 527.
  48. Tsokos G.C. B cells, be gone: B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med. 2004; 350: 2546-2548.
  49. Shemesh O., Ross J.C., Deen W.M. et al. Nature of the glomerular capillary injury in human membranous glomerulopathy. J Clin Invest. 1986; 77: 868-877.
  50. Makker S.P., Kanalas J.J. Course of transplanted Heymann nephritis kidney in normal host: implications for mechanism of proteinuria in membranous glomerulonephropathy. J Immunol. 1989; 142: 3406-3410.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies